Literature DB >> 19663766

Efficacy and safety of the combination of docetaxel (Taxotere) with targeted therapies in the treatment of solid malignancies.

Vincenzo Emanuele Chiuri1, Nicola Silvestris, Vito Lorusso, Andrea Tinelli.   

Abstract

Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors. Numerous novel targeted drugs are being introduced in preclinical and clinical practice, aiming to directly inhibit pathways responsible for the maintenance of transformed and immortalized phenotypes of cancer cells. Herein we reported the efficacy and safety results of the most significant clinical trials evaluating different combinations and schedules of docetaxel plus biological therapeutics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19663766     DOI: 10.2174/138945009789578007

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  3 in total

1.  Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells.

Authors:  Zhiwei Wang; Yiwei Li; Aamir Ahmad; Sanjeev Banerjee; Asfar S Azmi; Dejuan Kong; Christine Wojewoda; Lucio Miele; Fazlul H Sarkar
Journal:  J Cell Biochem       Date:  2011-01       Impact factor: 4.429

Review 2.  Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.

Authors:  Zhiwei Wang; Yiwei Li; Aamir Ahmad; Asfar S Azmi; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2010-06-22

3.  Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells.

Authors:  Eleftheria Tsakalozou; Allison M Eckman; Younsoo Bae
Journal:  Biochem Res Int       Date:  2012-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.